Total Payments
$1,014
2024 Payments
$151.37
Companies
21
Transactions
59
Medicare Patients
3,138
Medicare Billing
$180,156
Payment Breakdown by Category
Food & Beverage$989.27 (97.5%)
Education$25.00 (2.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $989.27 | 58 | 97.5% |
| Education | $25.00 | 1 | 2.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $458.11 | 21 | $0 (2024) |
| Allergan, Inc. | $86.54 | 6 | $0 (2020) |
| Novo Nordisk Inc | $58.03 | 4 | $0 (2022) |
| Merck Sharp & Dohme LLC | $50.43 | 4 | $0 (2024) |
| PFIZER INC. | $39.14 | 3 | $0 (2021) |
| Currax Pharmaceuticals LLC | $38.76 | 2 | $0 (2023) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $33.94 | 2 | $0 (2024) |
| Amgen Inc. | $32.85 | 2 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $28.86 | 2 | $0 (2022) |
| AstraZeneca Pharmaceuticals LP | $24.12 | 2 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $151.37 | 7 | ABBVIE INC. ($120.48) |
| 2023 | $305.46 | 15 | ABBVIE INC. ($236.50) |
| 2022 | $166.50 | 9 | ABBVIE INC. ($86.40) |
| 2021 | $89.23 | 6 | Amgen Inc. ($32.85) |
| 2020 | $93.71 | 6 | Allergan, Inc. ($38.67) |
| 2019 | $109.27 | 8 | Allergan Inc. ($25.00) |
| 2018 | $39.64 | 3 | West-Ward Pharmaceuticals ($15.27) |
| 2017 | $59.09 | 5 | Novo Nordisk Inc ($23.82) |
All Payment Transactions
59 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.72 | General |
| Category: NEUROSCIENCE | ||||||
| 08/01/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $15.42 | General |
| Category: NEUROSCIENCE | ||||||
| 06/12/2024 | Merck Sharp & Dohme LLC | GARDASIL (Biological), VAXNEUVANCE, GARDASIL 9 | Food and Beverage | In-kind items and services | $13.75 | General |
| Category: VACCINE | ||||||
| 03/20/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $29.85 | General |
| Category: NEUROSCIENCE | ||||||
| 02/21/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $17.14 | General |
| Category: DIABETES | ||||||
| 02/07/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $31.83 | General |
| Category: NEUROSCIENCE | ||||||
| 01/03/2024 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $13.66 | General |
| Category: NEUROSCIENCE | ||||||
| 12/13/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $25.32 | General |
| Category: NEUROSCIENCE | ||||||
| 11/16/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $14.08 | General |
| Category: NEUROSCIENCE | ||||||
| 10/25/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $30.28 | General |
| Category: NEUROSCIENCE | ||||||
| 10/05/2023 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: RESPIRATORY | ||||||
| 09/21/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $24.42 | General |
| Category: NEUROSCIENCE | ||||||
| 09/13/2023 | ABBVIE INC. | UBRELVY (Drug) | Food and Beverage | In-kind items and services | $18.43 | General |
| Category: NEUROSCIENCE | ||||||
| 08/17/2023 | Currax Pharmaceuticals LLC | NEXLETOL (Drug) | Education | In-kind items and services | $25.00 | General |
| Category: Cholesterol Reducer | ||||||
| 08/17/2023 | Currax Pharmaceuticals LLC | CONTRAVE (Drug), NEXLETOL, NEXLIZET | Food and Beverage | In-kind items and services | $13.76 | General |
| Category: Obesity | ||||||
| 07/12/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $21.54 | General |
| Category: NEUROSCIENCE | ||||||
| 06/14/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $19.63 | General |
| Category: NEUROSCIENCE | ||||||
| 05/24/2023 | Abbott Laboratories | FREESTYLE LIBRE 2 (Device) | Food and Beverage | In-kind items and services | $16.81 | General |
| Category: Diabetes Care | ||||||
| 05/03/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.81 | General |
| Category: NEUROSCIENCE | ||||||
| 04/19/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $18.96 | General |
| Category: NEUROSCIENCE | ||||||
| 03/23/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $16.89 | General |
| Category: NEUROSCIENCE | ||||||
| 01/17/2023 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $23.14 | General |
| Category: NEUROSCIENCE | ||||||
| 09/21/2022 | ABBVIE INC. | VRAYLAR (Drug) | Food and Beverage | In-kind items and services | $17.98 | General |
| Category: NEUROSCIENCE | ||||||
| 07/27/2022 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $19.32 | General |
| 06/29/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $14.89 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 15 | 653 | 852 | $141,607 | $33,169 |
| 2022 | 19 | 723 | 941 | $151,644 | $38,932 |
| 2021 | 19 | 874 | 1,176 | $144,940 | $56,987 |
| 2020 | 17 | 888 | 1,204 | $134,547 | $51,069 |
Total Patients
3,138
Total Services
4,173
Medicare Billing
$180,156
Procedure Codes
70
All Medicare Procedures & Services
70 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 155 | 306 | $55,080 | $12,004 | 21.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 88 | 115 | $15,525 | $4,535 | 29.2% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2023 | 57 | 59 | $6,490 | $4,230 | 65.2% |
| 91320 | Sarscv2 vac 30mcg trs-suc im | Office | 2023 | 26 | 26 | $7,514 | $3,340 | 44.5% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 62 | 65 | $2,470 | $1,859 | 75.3% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 15 | 15 | $5,295 | $1,682 | 31.8% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 17 | 29 | $3,683 | $1,644 | 44.6% |
| 90480 | Admn sarscov2 vacc 1 dose | Office | 2023 | 26 | 26 | $2,340 | $991.12 | 42.4% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2023 | 11 | 11 | $2,057 | $918.76 | 44.7% |
| 99495 | Transitional care management services for problem of at least moderate complexity | Office | 2023 | 19 | 19 | $6,555 | $728.65 | 11.1% |
| 0124A | Adm sarscv2 bvl 30mcg/.3ml a | Office | 2023 | 12 | 12 | $1,080 | $457.44 | 42.4% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 119 | 119 | $32,725 | $436.05 | 1.3% |
| 83036 | Hemoglobin a1c level | Office | 2023 | 14 | 16 | $368.00 | $152.32 | 41.4% |
| 82044 | Urine microalbumin (protein) analysis | Office | 2023 | 16 | 17 | $204.00 | $103.87 | 50.9% |
| 82570 | Creatinine level to test for kidney function or muscle injury | Office | 2023 | 16 | 17 | $221.00 | $86.36 | 39.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 151 | 316 | $55,928 | $12,261 | 21.9% |
| 90677 | Pneumococcal conjugate vaccine, 20 valent (pcv20), for intramuscular use | Office | 2022 | 18 | 18 | $9,279 | $5,030 | 54.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 93 | 130 | $16,846 | $5,011 | 29.7% |
| 90662 | Influenza vaccine split virus, preservative free | Office | 2022 | 61 | 61 | $6,710 | $4,174 | 62.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 14 | 14 | $4,942 | $2,069 | 41.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 66 | 66 | $2,508 | $1,779 | 70.9% |
| 0124A | Fee covid-19 vac 13 res | Office | 2022 | 35 | 35 | $3,150 | $1,247 | 39.6% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 22 | $2,794 | $1,201 | 43.0% |
| 0054A | Adm sarscv2 30mcg trs-sucr b | Office | 2022 | 27 | 28 | $2,520 | $1,006 | 39.9% |
| 99239 | Hospital discharge day management, more than 30 minutes | Facility | 2022 | 11 | 11 | $2,057 | $879.75 | 42.8% |
About Dr. Mark Kolar, M.D
Dr. Mark Kolar, M.D is a Family Medicine healthcare provider based in Burlington, Kentucky. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1356389829.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Kolar, M.D has received a total of $1,014 in payments from pharmaceutical and medical device companies, with $151.37 received in 2024. These payments were reported across 59 transactions from 21 companies. The most common payment nature is "Food and Beverage" ($989.27).
As a Medicare-enrolled provider, Kolar has provided services to 3,138 Medicare beneficiaries, totaling 4,173 services with total Medicare billing of $180,156. Data is available for 4 years (2020–2023), covering 70 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Burlington, KY
- Active Since 06/04/2006
- Last Updated 09/10/2018
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1356389829
Products in Payments
- VRAYLAR (Drug) $454.60
- UBRELVY (Drug) $41.05
- JARDIANCE (Drug) $33.94
- QULIPTA (Drug) $25.02
- NEXLETOL (Drug) $25.00
- PNEUMOVAX 23 (Biological) $24.67
- Levemir (Drug) $23.82
- Vascepa (Drug) $20.77
- MYRBETRIQ (Drug) $19.82
- Aimovig (Biological) $18.60
- FREESTYLE LIBRE 2 (Device) $16.81
- INTELLIS (Device) $16.34
- VYVANSE (Drug) $15.89
- PREMARIN (Drug) $15.50
- Mitigare (Drug) $15.27
- Ozempic (Drug) $14.89
- EVENITY (Biological) $14.25
- CONTRAVE (Drug) $13.76
- GARDASIL (Biological) $13.75
- TRELEGY ELLIPTA (Drug) $13.39
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Burlington
Krichna Sowles, Md, MD
Family Medicine — Payments: $17,218
Family Medicine $17,218
Dr. Jasmine Bajaj, Md, MD
Family Medicine — Payments: $8,590
Family Medicine $8,590
Dr. Richard Gilbert, Md, MD
Family Medicine — Payments: $7,905
Family Medicine $7,905
Michol Negron, D.o, D.O
Family Medicine — Payments: $7,588
Family Medicine $7,588
Dr. Donald Fisher, Md, MD
Family Medicine — Payments: $7,370
Family Medicine $7,370
Christopher Jarvis, M.d, M.D
Family Medicine — Payments: $5,691
Family Medicine $5,691